insights_auto
Outlook: 62.5% bullish·0.0% bearish
Go to analysischevron_right
BIIB:NASDAQ
Biogen Inc
$247.13
arrow_downward
-1.70%(-4.28) 1D
$247.13
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 19, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB...
Open
$251.26
High
$252.09
Low
$243.58
Mkt. cap
36.53B
Avg. vol.
1.24M
Volume
0.00
P/E ratio
105.79
52-wk high
$261.00
52-wk low
$160.36
EPS
$2.34
Beta
0.10
Shares outstanding
147.82M
No. of employees
8K
Open
$251.26
High
$252.09
Low
$243.58
Mkt. cap
36.53B
Avg. vol.
1.24M
Volume
0.00
P/E ratio
105.79
52-wk high
$261.00
52-wk low
$160.36
EPS
$2.34
Beta
0.10
Shares outstanding
147.82M
No. of employees
8K
News stories
From web sources and news partners
News Corp
·
9 hours ago
Biogen Inc. stock outperforms competitors despite losses on the day
Investing.com
·
17 hours ago
H.C. Wainwright reiterates Buy rating on Biogen stock at $270
Yahoo Finance
·
1 day ago
Biogen (BIIB) Posts Positive Two Year Diranersen Results And Five Year Lecanemab Data
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitebiogen.com